24 February

A new (and improved) model to regulate pharmaceutical promotion

12 February

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

31 January

Bayer CEO's callous comments highlight failure of current biomedical innovation model

31 January

Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed

30 January

Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed

23 January

Regulation critical to clinical trials data transparency in Europe

25 November

When politicians go to the movies

9 August

True clinical trials transparency? Not quite, EFPIA.

21 June

Good week for access to affordable medicines

15 May

Bracing for another delay – open innovation at the WHO?

2 December

EU Policy Opportunities in Biomedical Innovation and the Public Good

13 October

Statement on Medicines Patent Pool

2 August

Public Event on EU-MERCOSUR in Buenos Aires

14 July

The Diagnosis of Childhood Bipolar Disease has led to Catastrophic Consequences

12 July

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

20 May

Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN

17 May

Conflicts of Interest and the Future of Financing for WHO.

10 May

DG Trade public hearing on the “Protection and enforcement of IPR in third countries

29 April

EU-Mercosur Trade Negotiations: What Fate for Access to medicines?

29 April

Foundations: Conlicts of interests and Democracy issues

25 February

European drug regulator challenged over revolving door case involving former Director

1 February

Corporate funding linked to EU patient & consumer groups policy

20 December

EMA reviews transparency criteria

1 December

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

25 October

ACTA, Democracy & Access to Medicines

22 October

Selling Sickness through unbranded disease awareness campaigns?

22 October

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

22 October

Systematic review of drug promotion's influence on prescribing

18 October

Doha Declaration Par 6 to be reviewed in TRIPS Council

6 October

Welfare Implications of Intellectual Property Enforcement